ES2722852T3 - Una composición de galactooligosacáridos para uso en la prevención o el tratamiento de la disfunción cognitiva y alteraciones emocionales en neuropsiquiatría - Google Patents

Una composición de galactooligosacáridos para uso en la prevención o el tratamiento de la disfunción cognitiva y alteraciones emocionales en neuropsiquiatría Download PDF

Info

Publication number
ES2722852T3
ES2722852T3 ES14712715T ES14712715T ES2722852T3 ES 2722852 T3 ES2722852 T3 ES 2722852T3 ES 14712715 T ES14712715 T ES 14712715T ES 14712715 T ES14712715 T ES 14712715T ES 2722852 T3 ES2722852 T3 ES 2722852T3
Authority
ES
Spain
Prior art keywords
gal
prevention
treatment
composition
neuropsychiatry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14712715T
Other languages
English (en)
Inventor
Georgios Tzortzis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clasado Inc
Original Assignee
Clasado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clasado Inc filed Critical Clasado Inc
Application granted granted Critical
Publication of ES2722852T3 publication Critical patent/ES2722852T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Una composición de galactooligosacáridos que comprende disacáridos Gal (β1-3)-Glc; Gal (β1-3)-Gal; Gal (β1-6)- Gal; Gal (α;1-6)-Gal; trisacáridos Gal (β1-6)-Gal (β1-4)-Glc; Gal (β1-3)-Gal (β1-4)-Glc; tetrasacárido Gal (β1-6)-Gal (β1-6)-Gal (β1-4)-Glc y pentasacárido Gal (β1-6)-Gal (β1-6)-Gal (β1-6)-Gal (β1-4)-Glc para uso en la prevención o tratamiento de alteraciones emocionales en trastornos depresivos o trastornos de ansiedad.
ES14712715T 2013-03-28 2014-03-17 Una composición de galactooligosacáridos para uso en la prevención o el tratamiento de la disfunción cognitiva y alteraciones emocionales en neuropsiquiatría Active ES2722852T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1305708.8A GB201305708D0 (en) 2013-03-28 2013-03-28 Novel use
PCT/GB2014/050829 WO2014155056A1 (en) 2013-03-28 2014-03-17 A galactooligosaccharide composition for use in preventing or treating cognitive dysfunction and emotional disturbances in neuropsychiatry illnesses or ageing

Publications (1)

Publication Number Publication Date
ES2722852T3 true ES2722852T3 (es) 2019-08-19

Family

ID=48444941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14712715T Active ES2722852T3 (es) 2013-03-28 2014-03-17 Una composición de galactooligosacáridos para uso en la prevención o el tratamiento de la disfunción cognitiva y alteraciones emocionales en neuropsiquiatría

Country Status (19)

Country Link
US (2) US11241449B2 (es)
EP (1) EP2978432B1 (es)
JP (1) JP6309612B2 (es)
KR (2) KR20210038701A (es)
CN (1) CN105073120A (es)
AR (1) AR095738A1 (es)
AU (1) AU2014242798B2 (es)
BR (1) BR112015024625A2 (es)
CA (1) CA2908230C (es)
ES (1) ES2722852T3 (es)
GB (2) GB201305708D0 (es)
HK (1) HK1204451A1 (es)
IL (1) IL241844B (es)
MX (1) MX2015013699A (es)
MY (1) MY175533A (es)
RU (1) RU2663696C2 (es)
SG (2) SG10201707152TA (es)
TW (1) TWI507198B (es)
WO (1) WO2014155056A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
EP2886140A1 (en) * 2013-12-17 2015-06-24 University of Limerick An apparatus for the extracorporeal treatment of blood
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
EP3969009A1 (en) * 2019-05-15 2022-03-23 N.V. Nutricia Beta-1,3'-galactosyllactose for the treatment of gut barrier function diseases
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途
GB2623335A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
DE602004006133T3 (de) 2003-06-30 2014-12-24 Clasado Inc. Neue galactooligosaccharidzusammensetzung und herstellung davon
CN101095698B (zh) * 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
ITMI20071214A1 (it) 2007-06-15 2008-12-16 S I I T Srl Servizio Internazi Composizioni a base di componenti prebiotici ed immunogenici per la prevenzione e il trattamento di disturbi gastroenterici da disbiosi e/o alterazioni della normale flora intestinale
WO2009116886A1 (ru) * 2008-03-18 2009-09-24 Dikovskiy Aleksander Vladimiro Фармацевтическая композиция и способ профилактики дисбиозов, ассоциированных с энтеральным приемом антибиотиков
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
GB0809921D0 (en) * 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
NZ595174A (en) 2009-03-13 2013-04-26 Univ California Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut
WO2011053831A1 (en) * 2009-10-30 2011-05-05 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CN104206946A (zh) * 2009-11-12 2014-12-17 雀巢产品技术援助有限公司 用于促进肠微生物群平衡和健康的营养组合物
US20120276208A1 (en) 2011-04-27 2012-11-01 University Of South Australia Acute cognitive and mood effects of plant polysaccharides in adult human subjects

Also Published As

Publication number Publication date
SG11201507668UA (en) 2015-10-29
BR112015024625A2 (pt) 2017-07-18
US20220143054A1 (en) 2022-05-12
EP2978432B1 (en) 2019-02-20
KR102235730B1 (ko) 2021-04-02
RU2015146305A (ru) 2017-05-04
RU2663696C2 (ru) 2018-08-08
JP6309612B2 (ja) 2018-04-11
AU2014242798B2 (en) 2018-07-05
TW201444562A (zh) 2014-12-01
CA2908230A1 (en) 2014-10-02
AR095738A1 (es) 2015-11-04
HK1204451A1 (en) 2015-11-20
CA2908230C (en) 2021-04-13
CN105073120A (zh) 2015-11-18
GB2515865A (en) 2015-01-07
IL241844B (en) 2018-06-28
TWI507198B (zh) 2015-11-11
EP2978432A1 (en) 2016-02-03
MX2015013699A (es) 2016-05-31
GB201405503D0 (en) 2014-05-14
WO2014155056A1 (en) 2014-10-02
MY175533A (en) 2020-07-01
GB201305708D0 (en) 2013-05-15
KR20210038701A (ko) 2021-04-07
AU2014242798A1 (en) 2015-10-08
US11241449B2 (en) 2022-02-08
KR20150135504A (ko) 2015-12-02
SG10201707152TA (en) 2017-10-30
JP2016516743A (ja) 2016-06-09
GB2515865B (en) 2017-05-10
US20160045524A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
ES2722852T3 (es) Una composición de galactooligosacáridos para uso en la prevención o el tratamiento de la disfunción cognitiva y alteraciones emocionales en neuropsiquiatría
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CA2902714C (en) Bone screws and methods of use thereof
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112017003143A2 (pt) suspensões injetáveis e métodos para fabricação e uso das mesmas
GB2535413A (en) Sanitary tissue products
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
BR112014006707A2 (pt) artigos retrorrefletivos que incluem uma marca de segurança
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
AR069499A1 (es) Liquidos de ruptura y metodos para su uso
ES2689971T3 (es) Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento
BR112015031724A2 (pt) uso do antagonista do receptor nk-1 serlopitant em pruridos
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
MX2020009709A (es) Composiciones farmaceuticas que comprenden acido dihomo-gamma-linolenico (dgla) y uso de las mismas.
BR112015007750A2 (pt) sílicas tratadas e silicatos de metal para uma melhor limpeza em dentífrico
AR084051A1 (es) Derivados de 1-hidroxi-2-oxo-hidroquinolina, composiciones farmaceuticas que los contienen y uso de los mismos para tratar deficits cognitivos asociados con esquizofrenia y otros trastornos psiquiatricos y/o neurologicos
CL2015003433A1 (es) Derivados de tilosina y método para su preparación
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
BR112015018144A2 (pt) composição de emulsão água/óleo farmacêutica com gotículas de óleo manométricas, método para fazer a mesma e método para tratar um paciente em necessidade de uma única dose alta de clopidogrel